Pregnancy and Birth Outcomes in Patients With Multidrug-Resistant Tuberculosis Treated With Regimens That Include New and Repurposed Drugs
Ismat Lotia‐Farrukh, Nathalie Lachenal, Malik M Adenov, Saman Ahmed, Yerkebulan Algozhin, Sylvine Coutisson, Epifanio Sánchez Garavito, Catherine Hewison, David Holtzman, Helena Huerga, Aleeza Janmohamed, Palwasha Khan, Gamarly Leblanc Jacques, Nino Lomtadze, Nara Melikyan, Carole D. Mitnick, Gulnaz Mussabekova, Elna Osso, Sara Perea, Fauziah Asnely Putri, Mahmud Rashidov, Michael Rich, Yekaterina Sakhabutdinova, Kwonjune J. Seung, Assel Stambekova, Dante Vargas Vásquez, Molly F. Franke, Uzma Khan
Abstract
Among 43 pregnant women receiving multidrug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB) treatment with bedaquiline and/or delamanid, 98% had favorable treatment outcomes. Of 31 continued pregnancies, 81% had live births with no reported malformations, and 68% of neonates had normal birth weights. Effective MDR/RR-TB treatment during pregnancy can improve maternal outcomes without harming neonates.